"Fluoroquinolones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of QUINOLONES with at least one fluorine atom and a piperazinyl group.
Descriptor ID |
D024841
|
MeSH Number(s) |
D03.633.100.810.835.322
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fluoroquinolones".
Below are MeSH descriptors whose meaning is more specific than "Fluoroquinolones".
This graph shows the total number of publications written about "Fluoroquinolones" by people in this website by year, and whether "Fluoroquinolones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1998 | 1 | 0 | 1 |
1999 | 1 | 0 | 1 |
2000 | 1 | 0 | 1 |
2002 | 1 | 1 | 2 |
2003 | 3 | 0 | 3 |
2006 | 1 | 1 | 2 |
2008 | 0 | 1 | 1 |
2009 | 1 | 1 | 2 |
2011 | 1 | 0 | 1 |
2013 | 1 | 1 | 2 |
2014 | 1 | 0 | 1 |
2015 | 1 | 1 | 2 |
2016 | 7 | 0 | 7 |
2017 | 0 | 1 | 1 |
2018 | 1 | 0 | 1 |
2019 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluoroquinolones" by people in Profiles.
-
Antipseudomonal treatment decisions during CF exacerbation management. J Cyst Fibros. 2022 09; 21(5):753-758.
-
Fluoroquinolone-Associated Disability and Other Fluoroquinolone-Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years. Cancer Treat Res. 2022; 184:1-39.
-
A New Criterion for Fluoroquinolone-Associated Disability Diagnosis: Functional Gastrointestinal Disorders. Medicina (Kaunas). 2021 Dec 16; 57(12).
-
Empirical fluoroquinolones versus broad-spectrum beta-lactams for Gram-negative bloodstream infections in the absence of antimicrobial resistance risk factors. J Glob Antimicrob Resist. 2020 09; 22:87-93.
-
Fluoroquinolone-associated suicide. Eur J Intern Med. 2018 09; 55:e21-e22.
-
Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med. 2017 09 14; 377(11):1043-1054.
-
Clinical Risk Score for Prediction of Extended-Spectrum ?-Lactamase-Producing Enterobacteriaceae in Bloodstream Isolates. Infect Control Hosp Epidemiol. 2017 03; 38(3):266-272.
-
Differential effect of prior ?-lactams and fluoroquinolones on risk of bloodstream infections secondary to Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2017 Jan; 87(1):87-91.
-
Comparison of ?-lactam plus aminoglycoside versus ?-lactam plus fluoroquinolone empirical therapy in serious nosocomial infections due to Gram-negative bacilli. J Chemother. 2017 Feb; 29(1):30-37.
-
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PLoS One. 2016; 11(5):e0154778.